Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: BALZIVA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for BALZIVA (norethindrone and ethinyl estradiol) from Teva Pharmaceuticals USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BALZIVA (NORETHINDRONE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for BALZIVA (NORETHINDRONE AND ETHINYL ESTRADIOL)